Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease

Remya Sreedhar, Somasundaram Arumugam, Rajarajan Amirthalingam Thandavarayan, Vengadeshprabhu Karuppagounder, Kenichi Watanabe

Research output: Contribution to journalReview article

39 Scopus citations

Abstract

Inflammatory bowel diseases (IBD), mainly Crohn's disease (CD) and ulcerative colitis (UC) are chronic ailments of the gastrointestinal tract, characterized by recurrent inflammation. Current therapeutic strategies are based on the mitigation of symptoms, including inflammatory remission and healing of mucosal manifestations. Extensive studies have suggested that continuous oxidative damage can lead to the inflammatory signaling cascade in IBD. Curcumin, a potent modulator of cell signaling, is popular for its antioxidant and anti-inflammatory activities, and has already been shown remarkable therapeutic results in IBD. Here, we review and discuss the effects of curcumin as a therapeutic agent in the chemoprevention of IBD.

Original languageEnglish (US)
Pages (from-to)843-849
Number of pages7
JournalDrug Discovery Today
Volume21
Issue number5
DOIs
StatePublished - May 1 2016

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this